The comparison of oncologic outcomes between metastatic upper tract @entity189 and @entity189 of the bladder after XXXX -based chemotherapy.

@entity1 @entity632 @entity900 @entity189 @entity1349 @entity3 @entity1499 @entity136 @entity5713
OBJECTIVE: To compare the oncologic outcomes and prognostic factors between metastatic upper tract @entity189 (UTUC) and UC of the bladder (UCB) after @entity900 -based chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed @entity1 with metastatic UTUC and UCB after @entity1499 / @entity5713 / @entity632 / @entity900 (MVAC) or @entity136 / @entity900 chemotherapy between 1997 and 2014 at Kaohsiung Chang Gung Memorial Hospital. Progression-free survival (PFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazard models were also performed to assess the effect of prognostic factors. RESULTS: Totally, 203 @entity1 were enrolled into our study, including 120 @entity1 with UTUC and 83 @entity1 with UCB. For @entity1 with UTUC, the median PFS was 7.3 months vs. 4.0 months (P<0.001), and the median @entity1349 was 17.0 months vs. 10.5 months (P<0.001) for MVAC and @entity136 / @entity900 , respectively. For @entity1 with UCB, the median PFS (P = 0.35) and @entity1349 (P = 0.06) of the 2 groups were insignificant. In multivariate analyses, number of metastatic sites was the identical prognostic factor for @entity1349 between UTUC (hazard ratio [HR] = 2.74; 95% CI: 1.63-4.62; P<0.001) and UCB (HR = 3.12; 95% CI: 1.52-6.39; P = 0.002). Presence of liver @entity3 (HR = 1.84; 95% CI: 1.05-2.23; P = 0.03) and MVAC chemotherapy (HR = 0.54; 95% CI: 0.35-0.83; P<0.001) were significantly correlated to survival only for UTUC, not for UCB. CONCLUSION: Our study suggests discordant oncologic outcomes and prognostic factors between metastatic UTUC and UCB after @entity900 -based chemotherapy. A prospective study is warranted to validate our results.
